Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALVR |
---|---|---|
09:32 ET | 1000 | 0.74 |
09:36 ET | 100 | 0.7669 |
09:39 ET | 100 | 0.74 |
09:41 ET | 50040 | 0.735 |
10:06 ET | 1085 | 0.7354 |
10:10 ET | 500 | 0.7614 |
10:17 ET | 100 | 0.7402 |
10:19 ET | 1064 | 0.7605 |
10:21 ET | 100 | 0.7408 |
10:26 ET | 100 | 0.7409 |
10:28 ET | 100 | 0.75075 |
10:30 ET | 100 | 0.7506 |
10:33 ET | 100 | 0.7409 |
10:37 ET | 300 | 0.7506 |
10:39 ET | 200 | 0.7506 |
10:42 ET | 100 | 0.7506 |
10:44 ET | 200 | 0.7506 |
10:46 ET | 100 | 0.7506 |
10:48 ET | 400 | 0.7605 |
10:50 ET | 100 | 0.7506 |
10:53 ET | 100 | 0.7506 |
10:57 ET | 7718 | 0.7503 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Allovir Inc | 86.3M | -0.4x | --- |
Reviva Pharmaceuticals Holdings, Inc. | 89.3M | -1.9x | --- |
PMV Pharmaceuticals Inc | 82.8M | -1.1x | --- |
CEL-SCI Corp | 81.0M | -2.3x | --- |
Athira Pharma Inc | 80.9M | -0.7x | --- |
Allakos Inc | 93.1M | -0.5x | --- |
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $86.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 114.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.80 |
EPS | $-1.83 |
Book Value | $1.28 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.